How were Chiasma's earnings last quarter?

Chiasma, Inc. (NASDAQ:CHMA) issued its earnings results on Thursday, May, 6th. The biotechnology company reported ($0.49) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.31) by $0.18. The biotechnology company had revenue of $1.92 million for the quarter, compared to analysts' expectations of $1.80 million.

What other stocks do shareholders of Chiasma own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Chiasma investors own include Arbutus Biopharma (ABUS) , Bausch Health Companies (BHC) , GW Pharmaceuticals (GWPH) , BioDelivery Sciences International (BDSI) , Sorrento Therapeutics (SRNE) , SCYNEXIS (SCYX) , Viking Therapeutics (VKTX) , Amarin (AMRN) , Exelixis (EXEL) and Ovid Therapeutics (OVID) .

When did Chiasma IPO?

Chiasma (CHMA) raised $76 million in an initial public offering on Thursday, July 16th 2015. The company issued 5,400,000 shares at $13.00-$15.00 per share. Barclays and Cowen and Company acted as the underwriters for the IPO and William Blair and Oppenheimer & Co. were co-managers.

NASDAQ:CHMA

Chiasma (CHMA) Stock Price, News & Analysis

→ The Best AI Stock to Own in the World Today is Trading for Just $25 (From Banyan Hill Publishing) (Ad)

Free CHMA Stock Alerts

Notice: This company has been marked as potentially delisted and may not be actively trading.

Compare

Today's Range: $3.76
▼
$3.76
50-Day Range: $3.76
▼
$4.71
52-Week Range: $2.77
▼
$5.74

Volume: 147 shs
Average Volume: 2.12 million shs
Market Capitalization: $217.68 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: N/A

Stock Analysis

Get Chiasma alerts:

Ad InvestorPlace

New crypto project uncovers 2,050% in 65 days

During the event on Tuesday, April 23 at 10 am ET, I’ll be giving away the name and ticker symbol of crypto that could surge in price. I believe it will be the best performing crypto of 2024.

Just click here to sign up and be among the first to get it.

About Chiasma Stock (NASDAQ:CHMA)

Chiasma, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing oral medications using transient permeability enhancer technology platform for the treatment of rare and serious chronic disease worldwide. The company offers MYCAPSSA, an oral octreotide capsule for the long-term maintenance treatment in acromegaly patients who have responded to and tolerated treatment with octreotide or lanreotide. It also develops MPOWERED, an oral octreotide capsule, which has completed Phase III clinical trials for the maintenance treatment of adult patients with acromegaly. Chiasma, Inc. was incorporated in 2001 and is headquartered in Needham, Massachusetts.

Ad InvestorPlace

New crypto project uncovers 2,050% in 65 days

During the event on Tuesday, April 23 at 10 am ET, I’ll be giving away the name and ticker symbol of crypto that could surge in price. I believe it will be the best performing crypto of 2024.

Just click here to sign up and be among the first to get it.

CHMA Stock News Headlines

October 29, 2023 | thestreet.com

Chiasma Craters on FDA Drug Rejection

October 6, 2022 | globenewswire.com

Orphan Drugs Market Size to Hit USD 340.84 Billion by 2027 - GlobeNewswire

April 19, 2024 | InvestorPlace (Ad)

New crypto project uncovers 2,050% in 65 days

During the event on Tuesday, April 23 at 10 am ET, I’ll be giving away the name and ticker symbol of crypto that could surge in price. I believe it will be the best performing crypto of 2024.

September 28, 2022 | businesswire.com

Ironshore Announces Executive Appointments and Strengthening of the Global Business Management Team - Business Wire

September 16, 2022 | marketscreener.com

CHMP adopts positive opinion for Mycapssa® for the treatment of Acromegaly - Marketscreener.com

September 16, 2022 | streetinsider.com

Amryt (AMYT) Receives Positive CHMP Opinion for Mycapssa - StreetInsider.com

September 7, 2022 | uk.finance.yahoo.com

Amryt to Present Data from MPOWERED Phase 3 Trial of Mycapssa® (oral octreotide) at ENEA 2022 - Yahoo Finance UK

August 12, 2022 | gurufocus.com

MPM ASSET MANAGEMENT LLC Buys - GuruFocus.com

April 19, 2024 | InvestorPlace (Ad)

New crypto project uncovers 2,050% in 65 days

During the event on Tuesday, April 23 at 10 am ET, I’ll be giving away the name and ticker symbol of crypto that could surge in price. I believe it will be the best performing crypto of 2024.

August 4, 2022 | globenewswire.com

Amryt Reports Record Q2 2022 Results - GlobeNewswire

July 12, 2022 | businesswire.com

SpyBiotech Appoints Seasoned Biotech Executive Mark Leuchtenberger as Chief Executive Officer - Business Wire

July 12, 2022 | finance.yahoo.com

SpyBiotech Appoints Seasoned Biotech Executive Mark Leuchtenberger as Chief Executive Officer - Yahoo Finance

June 20, 2022 | finance.yahoo.com

Global Food Allergy Pipeline Insight | Clinical Trials Evaluation Research Report 2022 by DelveInsight - Yahoo Finance

June 18, 2022 | gurufocus.com

Amryt to Present Data from OPTIMAL and MPOWERED Phase 3 Trials Open Label Extension of Mycapssa® (oral octreotide) at ENDO 2022 - GuruFocus.com

June 16, 2022 | finance.yahoo.com

At 10.4% CAGR, Global Oral Proteins and Peptides Market Size & Share to Surpass USD 8.42 Billion by 2028 | Industry Trends, Growth, Value, Opportunities, Statistics, Analysis & Forecast Report by Zion Market Research - Yahoo Finance

June 15, 2022 | globenewswire.com

The oral proteins and peptides market is anticipated to grow at a CAGR of 20%, during 2022-2032, claims Roots Analysis - GlobeNewswire

June 15, 2022 | finance.yahoo.com

The oral proteins and peptides market is anticipated to grow at a CAGR of 20%, during 2022-2032, claims Roots Analysis - Yahoo Finance

June 8, 2022 | finance.yahoo.com

Amryt to Present Data from OPTIMAL and MPOWERED Phase 3 Trials Open Label Extension of Mycapssa® (oral octreotide) at ENDO 2022 - Yahoo Finance

May 13, 2022 | gurufocus.com

Top 5 1st Quarter Trades of MPM ASSET MANAGEMENT LLC - GuruFocus.com

May 6, 2022 | financialpost.com

Amryt Reports Record Q1 2022 Results - Financial Post

May 4, 2022 | globenewswire.com

Amryt Reports Record Q1 2022 Results - GlobeNewswire

May 4, 2022 | stockhouse.com

2022-05-04 | NDAQ:AMYT | Press Release | Amryt Pharma plc - Stockhouse

March 21, 2022 | benzinga.com

Insights on the Oral Proteins and Peptides Global Market to 2032 - Key Drivers and Challenges - Benzinga - Benzinga

March 16, 2022 | globenewswire.com

Global Oral Proteins and Peptides Market to 2032 - by - GlobeNewswire

March 11, 2022 | streetinsider.com

Amryt (AMYT) Reports FY Revenues of $222.5M, Growth of 22% - StreetInsider.com

March 9, 2022 | globenewswire.com

Amryt Announces 22% growth in FY 2021 Revenues to $222.5M - GlobeNewswire

February 28, 2022 | prnewswire.com

Warm Autoimmune Hemolytic Anemia Market is Expected to Witness Growth at an Accelerated CAGR of 14.7% in the 7MM for the Study Period 2018-30, Assesses DelveInsight - PRNewswire

See More Headlines

Receive CHMA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Chiasma and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 5/06/2021
Today: 4/18/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Pharmaceutical Preparations
Sub-Industry: N/A
Current Symbol: NASDAQ:CHMA
CUSIP: N/A
CIK: 1339469
Web: www.chiasmapharma.com
Phone: 617-928-5300
Fax: N/A
Employees: 85
Year Founded: N/A

Profitability

EPS (Most Recent Fiscal Year): ($1.43)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-74,780,000.00
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: -113.57%
Return on Assets: -57.62%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 7.91
Quick Ratio: 7.08

Sales & Book Value

Annual Sales: $1.11 million
Price / Sales: 196.11
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $1.59 per share
Price / Book: 2.36

Miscellaneous

Outstanding Shares: 57,894,000
Free Float: N/A
Market Cap: $217.68 million
Optionable: Not Optionable
Beta: 1.28

5G Stocks: The Path Forward is Profitable

Click the link below and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report

Key Executives

Mr. Raj Kannan (Age 56)
Pres, CEO & Director
Comp: $827.55k
Mr. Anand Varadan (Age 54)
Exec. VP & Chief Commercial Officer
Comp: $542.27k
Mr. John Brendan Doyle (Age 44)
Sr. VP, CFO & Treasurer
Mr. Drew Enamait (Age 47)
VP of Fin. & Admin.
Ms. Dawn Schottlandt CFA
VP of Investor Relations & Corp. Communications
Mr. Lee G. Giguere (Age 40)
VP, Gen. Counsel and Sec.
Mr. Derek Brown
VP of Marketing
Mr. Joe Lyons
Exec. Director of HR
Dr. William H. Ludlam (Age 55)
Sr. VP of Clinical Devel. & Medical Affairs
Mr. David M. Schubert
Sr. VP of Regulatory & Quality

Key Competitors

View All Competitors

CHMA Stock Analysis - Frequently Asked Questions

How were Chiasma's earnings last quarter?: Chiasma, Inc. (NASDAQ:CHMA) issued its earnings results on Thursday, May, 6th. The biotechnology company reported ($0.49) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.31) by $0.18. The biotechnology company had revenue of $1.92 million for the quarter, compared to analysts' expectations of $1.80 million.
What other stocks do shareholders of Chiasma own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Chiasma investors own include Arbutus Biopharma (ABUS), Bausch Health Companies (BHC), GW Pharmaceuticals (GWPH), BioDelivery Sciences International (BDSI), Sorrento Therapeutics (SRNE), SCYNEXIS (SCYX), Viking Therapeutics (VKTX), Amarin (AMRN), Exelixis (EXEL) and Ovid Therapeutics (OVID).
When did Chiasma IPO?: Chiasma (CHMA) raised $76 million in an initial public offering on Thursday, July 16th 2015. The company issued 5,400,000 shares at $13.00-$15.00 per share. Barclays and Cowen and Company acted as the underwriters for the IPO and William Blair and Oppenheimer & Co. were co-managers.

This page (NASDAQ:CHMA) was last updated on 4/19/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Chiasma (CHMA) Stock Price, News & Analysis

About Chiasma Stock (NASDAQ:CHMA)

CHMA Stock News Headlines

Company Calendar

Industry, Sector and Symbol

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

Key Competitors

CHMA Stock Analysis - Frequently Asked Questions

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info